Medulloblastoma (MB) is the most common malignant brain tumour of childhood affecting around 100 children each year in the UK. Investigating the mechanisms of disease relapse in MB with the aim of improving survival and developing future treatments.
It ran from 10:00 AM, 5 December 2013 to 5:00 PM, 18 December 2013
Registered Charity in England and Wales (208701)
Sadly, in around 40 per cent of patients treated for medulloblastoma (MB) the condition will recur. At present, the majority of patients with relapsed MB will die from their disease, as most existing treatments for relapsed MB can only prolong life and are not a cure.
The researchers will establish a group of up to 50 cases of patients with relapsed MB, where tumour tissue samples have been taken both at diagnosis and also when the cancer relapsed. They will be able to study theses using a variety of laboratory techniques and compare and correlate these results with the clinical information.
Please upgrade your browser to continue.